Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,726,649
  • Shares Outstanding, K 49,820
  • Annual Sales, $ 560,870 K
  • Annual Income, $ 82,590 K
  • 36-Month Beta 1.32
  • Price/Sales 4.84
  • Price/Cash Flow 19.45
  • Price/Book 3.08

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.81 +9.76%
on 06/28/18
55.31 -1.16%
on 07/16/18
+0.83 (+1.54%)
since 06/19/18
3-Month
46.93 +16.49%
on 05/04/18
55.94 -2.27%
on 06/14/18
+0.30 (+0.55%)
since 04/19/18
52-Week
32.48 +68.32%
on 08/11/17
55.94 -2.27%
on 06/14/18
+19.78 (+56.69%)
since 07/19/17

Most Recent Stories

More News
EBS vs. NEO: Which Stock Is the Better Value Option?

EBS vs. NEO: Which Stock Is the Better Value Option?

EBS : 54.67 (-0.11%)
NEO : 14.05 (+1.74%)
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference

Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will present a corporate overview and discuss recent business developments during a fireside...

EBS : 54.67 (-0.11%)
Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility

-- Multi-year investment will support growth of contract development and manufacturing capabilities

EBS : 54.67 (-0.11%)
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available

Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 24, 2018 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center,...

EBS : 54.67 (-0.11%)
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

LGND : 232.54 (+2.56%)
EBS : 54.67 (-0.11%)
GSK : 40.69 (-0.68%)
SNY : 41.91 (-0.38%)
What Lies Ahead for Ligand (LGND) This Earnings Season?

Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

LGND : 232.54 (+2.56%)
ADVM : 5.15 (+4.04%)
EBS : 54.67 (-0.11%)
NVS : 80.80 (-0.20%)
Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?

Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.

ADVM : 5.15 (+4.04%)
AZN : 37.03 (-0.80%)
EBS : 54.67 (-0.11%)
PRGO : 75.83 (-0.77%)
Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?

Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.

CELG : 85.34 (-0.51%)
ADVM : 5.15 (+4.04%)
JAZZ : 177.11 (+0.60%)
EBS : 54.67 (-0.11%)
What's in Store for Catalyst (CPRX) This Earnings Season?

Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.

CELG : 85.34 (-0.51%)
ADVM : 5.15 (+4.04%)
EBS : 54.67 (-0.11%)
CPRX : 3.08 (unch)
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?

In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.

ADVM : 5.15 (+4.04%)
EBS : 54.67 (-0.11%)
MDGL : 288.72 (+0.60%)
VNDA : 20.95 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EBS with:

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

2nd Resistance Point 55.70
1st Resistance Point 55.18
Last Price 54.67
1st Support Level 53.93
2nd Support Level 53.20

See More

52-Week High 55.94
Last Price 54.67
Fibonacci 61.8% 46.98
Fibonacci 50% 44.21
Fibonacci 38.2% 41.44
52-Week Low 32.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar